Substance / Medication

Ripretinib

Overview

Active Ingredient
ripretinib
RxNorm CUI
2369389

Indications

QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Labeler: Deciphera Pharmaceuticals, LLCUpdated: 2025-05-12T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Heinrich Michael C, Jones Robin L, George Suzanne et al. · Nat Med · 2024
PMID: 38182785RCTFull text (PMC)
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.
Kumar Vaibhav, Doros Leslie, Thompson Margaret et al. · Clin Cancer Res · 2023
PMID: 36485007RCTFull text (PMC)
[Relationship between ripretinib concentration and the prognosis of advanced gastrointestinal stromal tumors in China: a multicenter study].
Xu H, Sun X F, Qian H R et al. · Zhonghua Wei Chang Wai Ke Za Zhi · 2024
PMID: 39572178Observational
Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.
Zhang Xinhua, Zhang Peng, Qiu Haibo et al. · Adv Ther · 2023
PMID: 37356078ObservationalFull text (PMC)
Case Report: Neoadjuvant therapy with ripretinib for gastrointestinal stromal tumor: a case report.
Liu Guanmo, Zheng Zicheng, Li Jie et al. · Front Pharmacol · 2025
PMID: 40303927Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ripretinib (substance)
SNOMED CT
876860008
UMLS CUI
C5139749
RxNorm CUI
2369389
Labeler
Deciphera Pharmaceuticals, LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.